NCT01406509View on ClinicalTrials.gov

Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions
Healthy
Interventions
BIOLOGICAL

0.5ml/dose for a person

group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0

BIOLOGICAL

0.5ml/dose for a person

group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28

Trial Locations (1)

210009

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Royal (Wuxi) Biological Co., LTD

OTHER

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT01406509 - Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children | Biotech Hunter | Biotech Hunter